BCRX — BioCryst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.05bn
- $2.52bn
- $874.84m
Brief: BioCryst Pharmaceuticals Q1 EPS USD -0.17 Vs. IBES Estimate USD -0.21
BioCryst Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview
Bird flu testing shows more dairy products are safe, US FDA says (updated)
US health insurers rise on UnitedHealth's upbeat Q1 profit
BioCryst Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: BioCryst Pharmaceuticals Q4 EPS USD -0.31
BioCryst Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO
Brief: Biocryst Pharmaceuticals Updates Commercialization Agreement With Torii Pharmaceutical In Japan
Brief: Biocryst Pharmaceuticals - Orladeyo Generally Well Tolerated, And Safety Consistent With Entire Apex-S Population
BioCryst Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: BioCryst Pharmaceuticals Q3 EPS USD -0.19
BioCryst Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: BioCryst Begins Enrollment in Proof-of-Concept Trial of Oral Factor D Inhibitor, BCX10013
BioCryst Pharma gains as RBC upgrades rating, lifts PT
U.S. RESEARCH ROUNDUP-Airbnb, Cummins, Meta Platforms
BioCryst Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: BioCryst Pharmaceuticals Q2 EPS USD -0.4
BioCryst Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview